AMAGUS
Open
Back To Top
Last Updated: Nov 13, 2019 12:15 p.m. EST Real time quote

$9.60

0.385 4.18%
Health Care/Life Sciences 0.36%
Previous Close
$9.21
Advanced Charting
  • $
  • %
  • Vol
Advanced Charting
32.42% vs Avg.
Volume: 305.1K 65 Day Avg. - 941K
Open: 9.21
Last: 9.60
9.01 Day Low/High 9.64
Day Range
6.81 52 Week Low/High 19.44

Your Watchlist

Customize MarketWatch

Have Watchlists? Log in to see them here or sign up to get started.

Symbol
Company
Price
Chg/Chg %
No Items in Watchlist

There are currently no items in this Watchlist.

No Saved Watchlists

Create a list of the investments you want to track.

Uh oh

Something went wrong while loading Watchlist.

Recently Viewed Tickers

No Recent Tickers

Visit a quote page and your recently viewed tickers will be displayed here.

Key Data

  • Open $9.21
  • Day Range 9.01 - 9.64
  • 52 Week Range 6.81 - 19.44
  • Market Cap $313.72M
  • Shares Outstanding 33.77M
  • Public Float 29.18M
  • Beta 1.32
  • Rev. per Employee $1.01M
  • P/E Ratio n/a
  • EPS $-8.38
  • Yield n/a
  • Dividend n/a
  • Ex-Dividend Date n/a
  • Short Interest 13.31M 10/31/19
  • % of Float Shorted 45.62%
  • Average Volume 941.01K

Performance

5 Day
  • 6.73%
1 Month
  • -14.71%
3 Month
  • -21.09%
YTD
  • -36.83%
1 Year
  • -43.69%

Recent News

  • MarketWatch
  • WSJ
Read full story

Charting a bull-trend pullback: S&P, Dow retest the breakout point

Read full story

S&P 500 nails gap support (2,898) as August volatility spike fades

Read full story

Women’s Libido Drug Vyleesi Won FDA Approval, but Stock Investors Aren’t Happy

Palatin's stock reverses course, falls 6.4% after being up as much as 33% earlier

Palatin's stock rockets after FDA OK to market sexual desire disorder treatment

AMAG stock rallies on FDA approval for drug to increase women's sex drive

AMAG Pharmaceuticals started at hold with $14 stock price target at SunTrust RH

AMAG Pharmaceuticals stock down 6% after latest trial of Makena fails to meet primary endpoints

AMAG Pharmaceuticals downgraded to underweight from neutral at J.P. Morgan

AMAG Pharmaceuticals downgraded to neutral from buy at Janney

Palatin shares surge 9% premarket after FDA accepts for review treatment for HSDD

Palatin shares up 9% premarket

Palatin, Amag Pharma's treatment for female sexual desire disorder accepted for FDA review

Read full story

Stocks close higher for fifth straight session as Dow reclaims 25,000-level

Amag Pharmaceuticals upgraded to buy vs. neutral at Janney

Antares Pharma, Amag Pharma shares soar premarket after FDA approves auto injector

Antares Pharma, Amag Pharma shares soar premarket after FDA approves quickshot auto injector

Read full story

Health-care ETF tumbles, pressured by pharmaceutical company weakness

Read full story

Valeant has officially given up its $1 billion bet on the ‘female Viagra’

Read full story

15 companies with outsized sales growth and widening profit margins

Stocks to Watch: AMAG, Pinterest, Avis Budget

AMAG Pharmaceuticals, Pinterest and Avis Budget are among the companies with shares expected to trade actively in Friday’s session.

on The Wall Street Journal

Stocks to Watch: Apple, J&J, Fiat Chrysler, Mattel, Uber and More

Fiat Chrysler, Apple, Johnson & Johnson, Mattel and Uber are among the companies with shares expected to trade actively.

on The Wall Street Journal

FDA Committee Recommends Withdrawing Makena

A U.S. Food and Drug Administration advisory committee recommended that the standard treatment to prevent women from having another preterm birth, Makena, be withdrawn from the market in a 9-to-7 vote.

on The Wall Street Journal

Preterm Birth Treatment Isn’t Effective, Study Finds

The standard treatment to prevent women from having another preterm birth isn’t effective, according to the final results of a study. The finding has already led at least one maternal medicine group to revamp its guidelines.

on The Wall Street Journal
Read full story

Stocks to Watch: Caesars, Bristol-Myers, Carnival, FedEx, and More

on The Wall Street Journal
Read full story

New Doubt on Treatment to Prevent Preterm Birth

on The Wall Street Journal
Read full story

Stocks to Watch: Apple, Amazon, Alphabet, Cisco, Marriott, Applied Materials, Avon, Waste Management

on The Wall Street Journal
Read full story

Medivation Sets Wednesday as Cutoff for Vote on Sanofi’s Proposal to Remove Board

on The Wall Street Journal
Read full story

Hillary Clinton Tweet Sends Biotech Stocks Tumbling

on The Wall Street Journal
Read full story

CFO Moves: MicroStrategy, Keryx Biopharmaceuticals, Energy Focus

on The Wall Street Journal

The Morning Leverage: GTCR Sells Cord Blood Registry for $700 Million

on The Wall Street Journal
Read full story

Up and Down the Ladder: The Latest Comings and Goings at Alnylam, Valeant and…

on The Wall Street Journal
Read full story

Stocks to Watch: Abercrombie & Fitch, Avago Technologies, J&J

on The Wall Street Journal
Read full story

After Departures, Perella Aims to Rebuild

on The Wall Street Journal
Read full story

Amazon Starts Email Service for Companies

on The Wall Street Journal
Read full story

A Buyer’s Guide to Best Computers for Business

on The Wall Street Journal
Read full story

Stocks to Watch: DreamWorks Animation, Athlon Energy, Tibco Software

on The Wall Street Journal

Lumara Health to Sell Assets to AMAG, Perrigo for $757 Million

on The Wall Street Journal
Read full story

Up and Down the Ladder: The Latest Comings and Goings at AMAG, Takeda, FDA and…

on The Wall Street Journal
Read full story

Up and Down the Ladder: The Latest Comings and Goings at Medivir, Adamas and…

on The Wall Street Journal

Recent News

  • Other News
  • Press Releases

AMAG Sees Hammer Chart Pattern: Time to Buy?

AMAG Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

on Zacks.com

AMAG Q3 Loss Wider Than Expected, Revenues Lag Estimates

AMAG disappoints investors with earnings and sales miss in the third quarter.

on Zacks.com

AMAG Pharmaceuticals (AMAG) Reports Q3 Loss, Lags Revenue Estimates

AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of -37.25% and -5.78%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

on Zacks.com

10-Q: AMAG PHARMACEUTICALS, INC.

10-Q: AMAG PHARMACEUTICALS, INC.

on Edgar Online - (EDG = 10Q, 10K)

AMAG Pharmaceuticals, Inc. (AMAG) CEO Bill Heiden on Q3 2019 Results - Earnings Call Transcript

AMAG Pharmaceuticals, Inc. (AMAG) CEO Bill Heiden on Q3 2019 Results - Earnings Call Transcript

on Seeking Alpha

AMAG Pharma Q3 top-line down 31%

AMAG Pharma Q3 top-line down 31%

on Seeking Alpha

Stocks to Watch: AMAG, Pinterest, Avis Budget

AMAG Pharmaceuticals, Pinterest and Avis Budget are among the companies with shares expected to trade actively in Friday’s session.

on The Wall Street Journal

Notable earnings before Friday’s open

Notable earnings before Friday’s open

on Seeking Alpha

The Zacks Analyst Blog Highlights: Alexion, Amgen, Gilead and AMAG

The Zacks Analyst Blog Highlights: Alexion, Amgen, Gilead and AMAG

on Zacks.com

Midday Gainers / Losers

Midday Gainers / Losers

on Seeking Alpha

Biotech Stock Roundup: Q3 Earnings Beat at ALXN & AMGN, Pipeline Updates & More

Key highlights include earnings updates, collaboration deals, and regulatory and pipeline updates.

on Zacks.com

What's in Store for GW Pharmaceuticals (GWPH) in Q3 Earnings?

Developments in Epidolex are likely to have aided GW Pharmaceuticals' (GWPH) performance in the third quarter.

on Zacks.com

EXAS, SAN among premarket losers

EXAS, SAN among premarket losers

on Seeking Alpha

Top Analyst Upgrades and Downgrades: AMD, Apple, Biomarin, Corning, EA, FireEye, Grubhub, Nordstrom, NXP, Shopify, Xerox and More

Wednesday's top analyst upgrades, downgrades and initiations included Advanced Micro Devices, Apple, Biomarin, Corning, Electronic Arts, FireEye, Grubhub, Nordstrom, NXP Semiconductors, Shopify and Xerox.

on 247WallSt.com

Stocks to Watch: Apple, J&J, Fiat Chrysler, Mattel, Uber and More

Fiat Chrysler, Apple, Johnson & Johnson, Mattel and Uber are among the companies with shares expected to trade actively.

on The Wall Street Journal

FDA Committee Recommends Withdrawing Makena

A U.S. Food and Drug Administration advisory committee recommended that the standard treatment to prevent women from having another preterm birth, Makena, be withdrawn from the market in a 9-to-7 vote.

on The Wall Street Journal

FDA Ad Com thumbs down on full Makena approval

FDA Ad Com thumbs down on full Makena approval

on Seeking Alpha

Is a Beat in Store for Amarin (AMRN) This Earnings Season?

Amarin's (AMRN) third-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.

on Zacks.com

AMAG Pharmaceuticals, Inc. (AMAG) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in AMAG Pharmaceuticals, Inc. (AMAG).

on Zacks.com

Amag Pharma shares halted pending outcome of Ad Com meeting

Amag Pharma shares halted pending outcome of Ad Com meeting

on Seeking Alpha

AMAG Pharmaceuticals to Present at Upcoming Investor Conferences

AMAG Pharmaceuticals to Present at Upcoming Investor Conferences

on GlobeNewswire

AMAG Pharmaceuticals to Present at Upcoming Investor Conferences

AMAG Pharmaceuticals to Present at Upcoming Investor Conferences

on GlobeNewswire

Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2020 Results and Provides Corporate Update

Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2020 Results and Provides Corporate Update

on PR Newswire - PRF

Antares Pharma to Present at the Jefferies 2019 London Healthcare Conference

Antares Pharma to Present at the Jefferies 2019 London Healthcare Conference

on GlobeNewswire

Antares Pharma to Present at the Jefferies 2019 London Healthcare Conference

Antares Pharma to Present at the Jefferies 2019 London Healthcare Conference

on GlobeNewswire

Intravenous (IV) Iron Drugs Market: Key Facts and Forecast Predictions Presented Until 2025

Intravenous (IV) Iron Drugs Market: Key Facts and Forecast Predictions Presented Until 2025

on AmericaNewsHour

Intravenous (IV) Iron Drugs Market: Key Facts and Forecast Predictions Presented Until 2022

Intravenous (IV) Iron Drugs Market: Key Facts and Forecast Predictions Presented Until 2022

on AmericaNewsHour

Cell Banking Outsourcing Market: Industry Development Scenario and Forecast to 2025

Cell Banking Outsourcing Market: Industry Development Scenario and Forecast to 2025

on AmericaNewsHour

Intravenous Iron Drugs Market 2019 Key Players, Trends, Share, Industry Size, Segmentation and Opportunities Forecast To 2026

Intravenous Iron Drugs Market 2019 Key Players, Trends, Share, Industry Size, Segmentation and Opportunities Forecast To 2026

on ABNewswire

Intravenous (IV) Iron Drugs Market Outlook and Growth Stance Forecasted Through 2022

Intravenous (IV) Iron Drugs Market Outlook and Growth Stance Forecasted Through 2022

on AmericaNewsHour

Intravenous (IV) Iron Drugs Market Outlook and Growth Stance Forecasted Through 2022

Intravenous (IV) Iron Drugs Market Outlook and Growth Stance Forecasted Through 2022

on AmericaNewsHour

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AMAG Pharmaceuticals, Inc. - AMAG

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AMAG Pharmaceuticals, Inc. - AMAG

on GlobeNewswire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AMAG Pharmaceuticals, Inc. - AMAG

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AMAG Pharmaceuticals, Inc. - AMAG

on GlobeNewswire

Preeclampsia Therapeutics Market to Expand with Rising Prevalence of Genetic Disorders

Preeclampsia Therapeutics Market to Expand with Rising Prevalence of Genetic Disorders

on The Express Wire

Stem Cell Banking Market expected to succeed CAGR of 12.76% until 2023, Current business standing in Healthcare, Pharmaceuticals Sector .

Stem Cell Banking Market expected to succeed CAGR of 12.76% until 2023, Current business standing in Healthcare, Pharmaceuticals Sector .

on The Express Wire

Intravenous (IV) Iron Drugs Market Size, Statistics, Growth, Revenue – Industry Forecast 2019-2026

Intravenous (IV) Iron Drugs Market Size, Statistics, Growth, Revenue – Industry Forecast 2019-2026

on Market Prediction

Nanoparticles in Biotechnology and Pharmaceuticals Market Size and Forecast 2026 | SWOT Analysis, Key Insights and Company Profiles

Nanoparticles in Biotechnology and Pharmaceuticals Market Size and Forecast 2026 | SWOT Analysis, Key Insights and Company Profiles

on Global QYResearch

CA 125 Test Market 2019 Analysis and Depth Research Recent Trends, Size, Share, Growth Factors and Forecast to 2024

CA 125 Test Market 2019 Analysis and Depth Research Recent Trends, Size, Share, Growth Factors and Forecast to 2024

on Heraldkeepers

Antares Pharma Reports Third Quarter 2019 Operating and Financial Results

Antares Pharma Reports Third Quarter 2019 Operating and Financial Results

on GlobeNewswire

Intravenous (IV) Iron Drugs Market Industry Trends, Share, Size and Forecast Report By 2023

Intravenous (IV) Iron Drugs Market Industry Trends, Share, Size and Forecast Report By 2023

on AmericaNewsHour

AMAG Pharmaceuticals Inc.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the research, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. Its products include Intrarosa, Vyleesi, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA. (See Full Profile)

Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 9 Full Ratings

Competitors

Name Chg % Market Cap
AmerisourceBergen Corp. 1.33% $17.51B
TherapeuticsMD Inc. 0.30% $772.7M
Hologic Inc. 2.11% $12.19B
Sanofi ADR -0.63% $114.91B
Rockwell Medical Inc. -3.06% $121.91M
Competitor Data Provided ByCapital Cube Logo